SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (66)8/28/1998 10:50:00 PM
From: james  Respond to of 1073
 
mz, long time without exchangeing punches <<g>>. Greetings!

<<Their cash position is not great (this is my main cancer for near-future, possibility for additional secondary), but recent deal with Taiho suggest that they can sign financially significant and important collaboration>>

My main concern of bts, in general, is that they tend to spend all the $$$ of the future deals before they get them. Just like me, shell out all my Sept pay-checks already.

The sole focus on one 'hot' target may just be too risky, even though, it might hit jackpot.

regards



To: Miljenko Zuanic who wrote (66)9/3/1998 10:49:00 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 1073
 
Miljenko:

CRXA also has a diagnostic position with Her-2?? I'm not certain of that, but......

biz.yahoo.com

Also relevant to this thread, OSIP is planning to launch a Her-2 diagnostic. So, Oncor, Corixa, OSI Pharmaceuticals...... is anyone else climbing on the GNE bandwagon?

Rick